FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)

DRUG2 trials

Conditions

Breast CancerCRCColorectal CarcinomaMelanomaNon-small Cell Lung CarcinomaOvarian CancerPancreatic CarcinomaProstate Cancer

Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

CompletedNCT02009449

Eli Lilly and CompanyBreast Cancer, Colorectal Carcinoma, Melanoma +6

Start: 2013-11-15End: 2023-07-22Updated: 2024-11-15

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

RecruitingNCT07204574

Chang Gung Memorial HospitalCRC

Start: 2025-05-14End: 2025-12-31Target: 40Updated: 2025-10-02

Investigational New Drugs2020-09-1014 citations

Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).

Journal of Clinical Oncology2020-05-202 citations

Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

Journal of Clinical Oncology2020-05-201 citations

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Journal of Clinical Oncology2020-02-191 citations

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

2019-09-25100 citations

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-013 citations

Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of Oncology2018-10-012 citations

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of Oncology2018-10-011 citations

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-01

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of Oncology2018-10-01

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Journal of Clinical Oncology2018-05-2010 citations

Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2018-05-207 citations

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.

Journal of Clinical Oncology2018-05-203 citations

Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2018-02-0113 citations

PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.

Journal of Clinical Oncology2017-05-204 citations

Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2017-05-202 citations

Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.

Journal of Clinical Oncology2017-05-201 citations

Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.

Journal of Clinical Oncology2017-05-20

PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer.

Journal of Clinical Oncology2017-05-20

Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.

Journal of Clinical Oncology2017-03-01

7 more papers not shown

FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)

Sponsors

Conditions

Phase 1

Related Papers